<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02098252</url>
  </required_header>
  <id_info>
    <org_study_id>13.315</org_study_id>
    <nct_id>NCT02098252</nct_id>
  </id_info>
  <brief_title>Treatment of Brain AVMs (TOBAS) Study</brief_title>
  <acronym>TOBAS</acronym>
  <official_title>Treatment of Brain AVMs (TOBAS) Study: A Randomized Controlled Trial and Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Régional et Universitaire de Brest</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study and registry are to offer the best management possible for
      patients with brain arteriovenous malformations (AVMs) (ruptured or unruptured) in terms of
      long-term outcomes, despite the presence of uncertainty. Management may include
      interventional therapy (with endovascular procedures, neurosurgery, or radiotherapy, alone or
      in combination) or conservative management.

      The trial has been designed to test a) whether medical management or interventional therapy
      will reduce the risk of death or debilitating stroke (due to hemorrhage or infarction) by an
      absolute magnitude of about 15% (over 10 years) for unruptured AVMs (from 30% to 15%); and,
      b) to test if endovascular treatment can improve the safety and efficacy of surgery or
      radiation therapy by at least 10% (80% to 90%).

      As for the nested trial on the role of embolization in the treatment of Brain AVMs by other
      means: the pre-surgical or pre-radiosurgery embolization of cerebral AVMs can decrease the
      number of treatment failures from 20% to 10%. In addition,embolization of cerebral AVMs can
      be accomplished with an acceptable risk, defined as permanent disabling neurological
      complications of 8%.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intracranial arteriovenous malformations (AVMs) are relatively uncommon but increasingly
      discovered lesions that can lead to significant neurological disability or death.1
      Population-based data suggest that the annual incidence of discovery of a symptomatic AVM is
      approximately 1.1 per 100 000 population.7. AVMs commonly present following an intracranial
      hemorrhage or seizure, although with contemporary brain imaging techniques, an increasing
      number of incidental lesions are found.2

      Intracranial AVMs are typically diagnosed before the age of 40 years old, with more than 50%
      of patients presenting following an intracranial hemorrhage, the most feared sequelae of
      harbouring an AVM.3 An AVM-related seizure is reported as the presenting feature in 20-25% of
      cases4, 5 and although these can sometimes be successfully managed with anti-epileptic
      agents, some AVMs lead to intractable seizures in spite of medication. Other presentations
      include headaches, focal neurological deficits, or pulsatile tinnitus.1

      The available natural history studies indicate an overall risk of initial hemorrhage of
      approximately 2% to 4% per year, although the long-term consequences in terms of the
      probability of death or long-term disability following intracranial hemorrhage remains
      unclear.6-8 Mortality from the first hemorrhage has been reported to occur between 10-30% of
      patients with a ruptured AVM, although some more recent data suggest that the mortality rate
      may be lower and only 10-20% of survivors have long-term disability.9-11 Hemorrhagic
      presentation is considered the most reliable risk factor for a repeat hemorrhage.6, 8
      Unfortunately, the natural history data available is not of sufficient quality (Level V) to
      support making management recommendations.

      Over the last decade, there have been substantial developments in the management of
      intracranial AVMs. There has been an evolution of microsurgical as well as endovascular and
      radiosurgical techniques to treat these lesions. As the management options have evolved,
      individual and combined modality treatment protocols have been developed in different
      institutions for the management of AVMs. Current interventional therapy for brain
      arteriovenous malformations (BAVMs) is varied and includes open neurosurgical resection,
      radiosurgery, and endovascular management, either alone or in combination. The choice of
      management is largely dependent on the decisions of the local physicians that make up the
      treatment team, and a recent survey has demonstrated substantial variability in
      decision-making for almost all AVMs.12

      Interventional therapies, when they are performed, are assumed to decrease the risk of
      initial or subsequent hemorrhage and therefore lead to better long-term outcomes, an
      assumption that has yet to be proven.

      Although the question of which AVM treatment modality is the most appropriate first choice
      (surgery, radiosurgery, or embolization) remains controversial, consensus can be reached in
      several circumstances. Surgical evacuation of a hematoma exerting significant mass effect is
      an uncontested appropriate management, although many patients with a hemorrhagic presentation
      do not necessarily meet this threshold for surgical indication. Almost all other management
      choices remain debatable.13, 14 A systematic review has proposed that approximately 7.1% of
      surgical candidates, 6.6% of endovascular candidates, and 5.1% of radiosurgical candidates
      were facing permanent neurological deficits after treatment.15 The epidemiological study of
      Davies et al, using the Nationwide Inpatient Sample (NIS) data base and surrogates such as
      location at discharge, showed worse outcomes for surgical and endovascular management of both
      ruptured and unruptured AVMs.16

      Current choices of interventional therapy for brain arteriovenous malformations are varied,
      with decisions made on a case-by-case basis, by the local clinical team. Often these
      decisions will change as the results of one particular attempted treatment modality become
      available. All interventional therapies are performed with the assumption that they will
      decrease the risk of initial or subsequent hemorrhage and lead to better long-term patient
      outcomes. Despite these laudable goals, there is no reliable evidence that interventional
      management of unruptured bAVMs is beneficial, and in patients judged to need interventional
      therapy, such as those patients presenting with ruptures, there is no randomized evidence
      that embolization is beneficial. Although no clinical trial data exist on the effect of
      interventional therapy even after AVM hemorrhage, the most contentious issue at present is
      whether interventional therapy should be considered for patients with incidentally discovered
      AVMs, whose lesions have not bled. In patients with unruptured AVMs, the best management
      strategy remains unknown, and interventions should be proposed only in the context of a
      randomized trial.

      The potential role of embolization: Although endovascular AVM embolization can occasionally
      eradicate lesions without surgery or radiation therapy in selected cases, and although
      embolization may potentially improve the safety and efficacy of surgical or radiosurgical
      treatments in some other cases, it remains a contentious issue whether it is worth accepting
      the additional risks of endovascular treatment for a greater overall benefit for patients
      with brain AVMs that are treatable by surgery or radiation therapy. Some series have reported
      satisfactory results.20 It is possible that the overall morbidity and mortality of the
      combined interventional management strategy is increased when embolization is added to a
      surgical or radiosurgical procedure.17 Therefore, pre-surgical or pre-radiosurgical
      embolization can be offered, but only as a randomized allocation between embolization and no
      embolization, within the context of a trial.

      Primary objective: In the spirit of care trials, the primary objective of the trial and
      accompanying registry is to offer the best management possible for patients with brain AVMs
      (ruptured or unruptured) in terms of long-term outcomes, despite the presence of uncertainty.
      Management may include interventional therapy (neurosurgery, or radiosurgery, alone or in
      combination, with or without endovascular procedures, alone or combined) or conservative
      management. An expert multidisciplinary study group will review patients on an individual
      basis to determine eligibility for the trial or registry parts of the study. The trial has
      been designed to test whether conservative management or interventional therapy will reduce
      the risk of disabling stroke or death.

      Secondary objectives: To determine if interventional management is effective in the
      prevention of neurological events during 10 years. To determine the morbidity and mortality
      related to therapy. To follow-up and record the neurological events and the neurological
      status of all patients with brain AVMs recruited and managed in our institutions, regardless
      of management strategy chosen.

      Hypotheses

      A) Randomized comparison of interventional treatment and conservative management:

      Primary hypothesis: Treatment of cerebral AVMs can decrease the number of disabling
      neurological events caused by the presence of the AVM (excluding peri-operative
      complications) from 30 to 15% within 10 years. (n = 266 minima) Secondary hypothesis:
      Treatment of cerebral AVMs can be accomplished with an acceptable up-front risk, defined as
      the occurrence of a permanent disabling neurological complication in less than 15% of
      patients)

      B) Nested trial on the Role of embolization in the treatment of Brain AVMs by other means
      Primary hypothesis: Pre-surgical or pre-radiosurgery embolization of cerebral AVMs can
      decrease the number of treatment failures (failure to achieve angiographic cure) from 20% to
      10% (n= 440).

      Secondary hypothesis: Embolization of cerebral AVMs can be accomplished with an acceptable
      risk, defined as permanent disabling neurological complications of 8% (3.4 to 12.6%, 95%
      C.I.).

      The study design is a prospective, multi-center, randomized, controlled trial and registry.
      Treatment assignment will not be masked; Interim study results will be kept confidential. The
      primary outcome is the composite event of death from any cause or disabling stroke
      (hemorrhage or infarction revealed by imaging and resulting in mRS &gt;2). Functional outcome
      status will be measured by the Rankin Scale, a widely used outcome measure for stroke. The
      secondary measures of outcome include adverse events, ruptures, and angiographic occlusion of
      the lesion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">January 2036</completion_date>
  <primary_completion_date type="Anticipated">January 2035</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>composite event of death from any cause or disabling stroke</measure>
    <time_frame>up to 10 years post-treatment (or randomization)</time_frame>
    <description>death or disabling stroke due to hemorrhage or infarction as revealed by imaging and resulting in mRS &gt;2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>occurrence of any neurological event</measure>
    <time_frame>within 10 years following treatment (or after randomization)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Permanent disabling peri-operative complications</measure>
    <time_frame>within 31 days post-treatment</time_frame>
    <description>The incidence of permanent (more than 3 months) disabling (mRS &gt;2) peri-operative (within 31 days) complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Unruptured Brain Arteriovenous Malformation</condition>
  <condition>Ruptured Brain Arteriovenous Malformation</condition>
  <condition>Arteriovenous Malformations</condition>
  <condition>AVM</condition>
  <condition>BAVM</condition>
  <arm_group>
    <arm_group_label>Interventional therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interventional therapies include:
neurosurgery (surgical resection when the lesion is considered by a multidisciplinary team to be safely 'operable'); radiation therapy (when the AVM is smaller than 3 cm, and considered to not be safely 'operable'); radiosurgery, alone or in combination, with or without endovascular procedure; curative embolization (when the lesion is considered curable by embolization).
Patients with AVMs that the multidisciplinary team judges could potentially benefit from endovascular treatment prior to surgical resection or radiation therapy will then also be pre-randomly allocated to embolization or to no embolization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conservative management (medical management)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The conservative, or medical management arm, involves pharmacological therapy as deemed appropriate for medical symptoms as determined by the treating investigator. Should patients in the conservative management arm develop hemorrhage or infarction related to their AVM, they then potentially become candidates for interventional therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Neurosurgery</intervention_name>
    <description>Surgical resection to be used when the lesion is considered by a multidisciplinary team to be safely 'operable'.</description>
    <arm_group_label>Interventional therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>when the AVM is smaller than 3 cm, and considered to not be safely 'operable'.</description>
    <arm_group_label>Interventional therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Embolization</intervention_name>
    <description>Curative embolization, when the lesion is considered curable by embolization.</description>
    <arm_group_label>Interventional therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient with a brain AVM

        Exclusion Criteria:

          -  Hemorrhagic presentation with mass effect requiring surgical management. In these
             cases, if a residual AVM is found after the initial surgery, the patient could then be
             a candidate for TOBAS.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Raymond, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUM-Montreal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean Raymond, MD</last_name>
    <phone>514-890-8000</phone>
    <phone_ext>27235</phone_ext>
    <email>jraymond.nri@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tim Darsaut, MD</last_name>
    <phone>780-407-1440</phone>
    <email>tdarsaut@ualberta.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thanh Nguyen, MD</last_name>
      <email>Thanh.Nguyen@bmc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Nolet</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>26359</phone_ext>
      <email>Suzanne.Nolet@crchum.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Ruby Klink, PhD</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>25245</phone_ext>
      <email>Ruby.Klink@crchum.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Jean Raymond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Roy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain Weill, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel Bojanowski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chiraz Chaalala, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Paul Bahary, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Roberge, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Masucci, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cynthia Ménard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Stapf, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest (Brest University Hospital)</name>
      <address>
        <city>Brest</city>
        <state>Bretagne</state>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elsa Magro, MD</last_name>
      <email>elsa.magro@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Elsa Magro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Christophe Gentric, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospit Régional Universitaire de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Biondi, MD</last_name>
      <email>biondi.alessandra@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Barreau, MD</last_name>
      <email>xavier.barreau@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Courtheoux, MD</last_name>
      <email>courtheoux-p@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis Turjman, MD</last_name>
      <email>drturjman@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Hugues Roche, MD</last_name>
      <email>pierre-hugues.roche@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Costalat, MD</last_name>
      <email>vincentcost@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serge Bracard, MD</last_name>
      <email>s.bracard@chru-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hubert Desal, MD</last_name>
      <email>hubert.desal@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Cornu, MD</last_name>
      <email>philippe.cornu@psl.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondation Ophtalmologique Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Piotin, MD</last_name>
      <email>mpiotin@for.paris</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Sainte-Anne</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Trystram, MD</last_name>
      <email>D.TRYSTRAM@ch-sainte-anne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Morandi, MD</last_name>
      <email>xavier.morandi@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Hôpitaux de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76130</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Papagiannaki, MD</last_name>
      <email>c.papagiannaki@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Les Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Proust, MD</last_name>
      <email>francois.proust@neurochirurgie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>70034</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Cognard, MD</last_name>
      <email>cognard.c@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Herbreteau, MD</last_name>
      <email>denis.herbreteau@univ-tours.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fleetwood IG, Steinberg GK. Arteriovenous malformations. Lancet. 2002 Mar 9;359(9309):863-73. Review.</citation>
    <PMID>11897302</PMID>
  </reference>
  <reference>
    <citation>Wedderburn CJ, van Beijnum J, Bhattacharya JJ, Counsell CE, Papanastassiou V, Ritchie V, Roberts RC, Sellar RJ, Warlow CP, Al-Shahi Salman R; SIVMS Collaborators. Outcome after interventional or conservative management of unruptured brain arteriovenous malformations: a prospective, population-based cohort study. Lancet Neurol. 2008 Mar;7(3):223-30. doi: 10.1016/S1474-4422(08)70026-7. Epub 2008 Feb 1.</citation>
    <PMID>18243054</PMID>
  </reference>
  <reference>
    <citation>Brown RD Jr, Wiebers DO, Torner JC, O'Fallon WM. Frequency of intracranial hemorrhage as a presenting symptom and subtype analysis: a population-based study of intracranial vascular malformations in Olmsted Country, Minnesota. J Neurosurg. 1996 Jul;85(1):29-32.</citation>
    <PMID>8683279</PMID>
  </reference>
  <reference>
    <citation>Brown RD Jr, Wiebers DO, Forbes G, O'Fallon WM, Piepgras DG, Marsh WR, Maciunas RJ. The natural history of unruptured intracranial arteriovenous malformations. J Neurosurg. 1988 Mar;68(3):352-7.</citation>
    <PMID>3343606</PMID>
  </reference>
  <reference>
    <citation>Wilkins RH. Natural history of intracranial vascular malformations: a review. Neurosurgery. 1985 Mar;16(3):421-30. Review.</citation>
    <PMID>3885072</PMID>
  </reference>
  <reference>
    <citation>da Costa L, Wallace MC, Ter Brugge KG, O'Kelly C, Willinsky RA, Tymianski M. The natural history and predictive features of hemorrhage from brain arteriovenous malformations. Stroke. 2009 Jan;40(1):100-5. doi: 10.1161/STROKEAHA.108.524678. Epub 2008 Nov 13.</citation>
    <PMID>19008469</PMID>
  </reference>
  <reference>
    <citation>Gross BA, Du R. Natural history of cerebral arteriovenous malformations: a meta-analysis. J Neurosurg. 2013 Feb;118(2):437-43. doi: 10.3171/2012.10.JNS121280. Epub 2012 Nov 30. Review.</citation>
    <PMID>23198804</PMID>
  </reference>
  <reference>
    <citation>Hernesniemi JA, Dashti R, Juvela S, Väärt K, Niemelä M, Laakso A. Natural history of brain arteriovenous malformations: a long-term follow-up study of risk of hemorrhage in 238 patients. Neurosurgery. 2008 Nov;63(5):823-9; discussion 829-31. doi: 10.1227/01.NEU.0000330401.82582.5E.</citation>
    <PMID>19005371</PMID>
  </reference>
  <reference>
    <citation>Hartmann A, Mast H, Mohr JP, Koennecke HC, Osipov A, Pile-Spellman J, Duong DH, Young WL. Morbidity of intracranial hemorrhage in patients with cerebral arteriovenous malformation. Stroke. 1998 May;29(5):931-4.</citation>
    <PMID>9596237</PMID>
  </reference>
  <reference>
    <citation>Hartmann A, Mast H, Mohr JP, Pile-Spellman J, Connolly ES, Sciacca RR, Khaw A, Stapf C. Determinants of staged endovascular and surgical treatment outcome of brain arteriovenous malformations. Stroke. 2005 Nov;36(11):2431-5. Epub 2005 Oct 13.</citation>
    <PMID>16224095</PMID>
  </reference>
  <reference>
    <citation>Hartmann A, Stapf C, Hofmeister C, Mohr JP, Sciacca RR, Stein BM, Faulstich A, Mast H. Determinants of neurological outcome after surgery for brain arteriovenous malformation. Stroke. 2000 Oct;31(10):2361-4.</citation>
    <PMID>11022064</PMID>
  </reference>
  <reference>
    <citation>Cockroft KM, Chang KE, Lehman EB, Harbaugh RE. AVM Management Equipoise Survey: physician opinions regarding the management of brain arteriovenous malformations. J Neurointerv Surg. 2014 Dec;6(10):748-53. doi: 10.1136/neurintsurg-2013-011030. Epub 2013 Dec 6.</citation>
    <PMID>24319022</PMID>
  </reference>
  <reference>
    <citation>Cockroft KM. Unruptured brain arteriovenous malformations should be treated conservatively: no. Stroke. 2007 Dec;38(12):3310-1. Epub 2007 Oct 25.</citation>
    <PMID>17962584</PMID>
  </reference>
  <reference>
    <citation>Stapf C, Mohr JP. Unruptured brain arteriovenous malformations should be treated conservatively: yes. Stroke. 2007 Dec;38(12):3308-9. Epub 2007 Oct 25.</citation>
    <PMID>17962585</PMID>
  </reference>
  <reference>
    <citation>van Beijnum J, van der Worp HB, Buis DR, Al-Shahi Salman R, Kappelle LJ, Rinkel GJ, van der Sprenkel JW, Vandertop WP, Algra A, Klijn CJ. Treatment of brain arteriovenous malformations: a systematic review and meta-analysis. JAMA. 2011 Nov 9;306(18):2011-9. doi: 10.1001/jama.2011.1632. Review.</citation>
    <PMID>22068993</PMID>
  </reference>
  <reference>
    <citation>Davies JM, Yanamadala V, Lawton MT. Comparative effectiveness of treatments for cerebral arteriovenous malformations: trends in nationwide outcomes from 2000 to 2009. Neurosurg Focus. 2012 Jul;33(1):E11. doi: 10.3171/2012.5.FOCUS12107.</citation>
    <PMID>22746228</PMID>
  </reference>
  <reference>
    <citation>Morgan MK, Davidson AS, Koustais S, Simons M, Ritson EA. The failure of preoperative ethylene-vinyl alcohol copolymer embolization to improve outcomes in arteriovenous malformation management: case series. J Neurosurg. 2013 May;118(5):969-77. doi: 10.3171/2012.11.JNS112064. Epub 2013 Jan 25.</citation>
    <PMID>23350776</PMID>
  </reference>
  <reference>
    <citation>Pierot L, Fiehler J, Cognard C, Söderman M, Spelle L. Will a randomized trial of unruptured brain arteriovenous malformations change our clinical practice? AJNR Am J Neuroradiol. 2014 Mar;35(3):416-7. doi: 10.3174/ajnr.A3867. Epub 2014 Jan 16.</citation>
    <PMID>24436345</PMID>
  </reference>
  <reference>
    <citation>Raymond J; TEAM collaborative group. Reflections on the TEAM trial: why clinical care and research should be reconciled. Can J Neurol Sci. 2011 Mar;38(2):198-202.</citation>
    <PMID>21320821</PMID>
  </reference>
  <reference>
    <citation>Saatci I, Geyik S, Yavuz K, Cekirge HS. Endovascular treatment of brain arteriovenous malformations with prolonged intranidal Onyx injection technique: long-term results in 350 consecutive patients with completed endovascular treatment course. J Neurosurg. 2011 Jul;115(1):78-88. doi: 10.3171/2011.2.JNS09830. Epub 2011 Apr 8.</citation>
    <PMID>21476804</PMID>
  </reference>
  <reference>
    <citation>Spetzler RF, Martin NA. A proposed grading system for arteriovenous malformations. J Neurosurg. 1986 Oct;65(4):476-83.</citation>
    <PMID>3760956</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2014</study_first_submitted>
  <study_first_submitted_qc>March 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2014</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</investigator_affiliation>
    <investigator_full_name>Jean Raymond</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>brain arteriovenous malformation</keyword>
  <keyword>Arteriovenous Malformations</keyword>
  <keyword>AVM</keyword>
  <keyword>BAVM</keyword>
  <keyword>Stroke</keyword>
  <keyword>Intracranial Hemorrhage</keyword>
  <keyword>Congenital Abnormalities</keyword>
  <keyword>Aneurysm</keyword>
  <keyword>Vascular Malformations</keyword>
  <keyword>Cardiovascular Abnormalities</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Vascular Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Arteriovenous Malformations</mesh_term>
    <mesh_term>Hemangioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

